AINEWS
The deal with China's Abogen sends big pharma capital into the mRNA chemistry behind Moderna's COVID vaccines, now aimed at chronic disease, structured after two late stage trial failures erased roughly $30 billion in market value.
Novartis is paying $575 million upfront to license an experimental drug from China's Abogen, with up to $7.2 billion more tied to clinical and regulatory milestones. The total, up to $7.8 billion, is the first big-pharma check on programmable RNA's move from COVID vaccines into chronic-disease therapeutics.
The asset, ABO2203, is an mRNA-encoded T-cell engager, a therapeutic class that turns the body's own cells into factories for proteins designed to redirect immune cells against disease targets. The platform is the same chemistry that powered Moderna's and Pfizer-BioNTech's COVID vaccines, but the application is different. Where the vaccines taught the platform to deliver genetic instructions to healthy cells for short-lived immune protection, the new wave of mRNA therapeutics aims to deliver those instructions chronically, in oncology and in autoimmune disease, where the immune system attacks the body's own tissues. Vaccines win on immune stimulation; autoimmune drugs win on immune restraint. Asking the same chemistry to do both is the bet the milestone payments are funding.
Abogen framed the platform as complementary to Novartis's existing autoimmune-disease portfolio. Novartis gains exclusive rights to ABO2203 plus options on additional RNA programs in Abogen's pipeline, according to the company's announcement.
The structure is best read against September. In the space of weeks, Novartis disclosed two late-stage trial failures that together erased roughly $30 billion in market capitalization, according to Bloomberg. A major shareholder publicly called for tighter board oversight of future acquisitions. A $575 million upfront against a $7.8 billion ceiling is proof-priced capital: Novartis pays for results, and the bulk of the consideration only arrives if the drug works.
Gillian Hollenstein, lead manager of the Point Capital Navigator Fund, a Novartis shareholder, told CNBC the structure carried a "better risk profile" because the upfront is small. She added that Novartis still needs later-stage deals with higher predictability, a holder-friendly note with a critic-friendly edge.
Shares of Novartis were 0.5% lower at 1250 GMT on the announcement day, in an otherwise subdued European pharmaceutical sector. The deal also extends to options on additional Abogen programs, which means the next round of clinical data, not the next quarter's revenue, is the watch item. The $7.2 billion in milestones is asking programmable RNA to prove the platform can move past pandemic medicine into chronic-disease therapeutics.